Anika Therapeutics (ANIK) Receivables - Net (2010 - 2026)

Anika Therapeutics (ANIK) has reported Receivables - Net for 17 consecutive years, with $29.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Net rose 19.83% year-over-year to $29.7 million in Q2 2026; TTM through Jun 2026 was $29.7 million, a 19.83% increase from a year earlier, with the FY2025 full-year figure at $24.8 million, up 2.03% from the prior year.
• Receivables - Net was $29.7 million for Q2 2026 at Anika Therapeutics, up from $26.9 million in the prior quarter.
• Over five years, Receivables - Net peaked at $38.4 million in Q2 2023 and troughed at $22.7 million in Q1 2025.
• A 5-year average of $29.8 million and a median of $29.7 million in 2026 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net sank 32.7% in 2025 and grew 19.83% in 2026, its largest moves.
• Over 5 years, Receivables - Net stood at $36.2 million in 2022, then declined by 25.41% to $27.0 million in 2023, then decreased by 10.0% to $24.3 million in 2024, then grew by 2.03% to $24.8 million in 2025, then advanced by 19.52% to $29.7 million in 2026.
• The last three Receivables - Net figures came in at $29.7 million (Q2 2026), $26.9 million (Q1 2026), and $24.8 million (Q4 2025), per Business Quant data.